Bictegravir is an integrase strand transfer inhibitor (INSTI) used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults [1]. As of now, there are no generic versions of bictegravir available on the market.
When Could Bictegravir Go Generic?
The availability of generic versions of a drug is typically linked to patent expiration and regulatory approval. Drug patents grant a period of market exclusivity, after which other companies can apply to produce generic versions. Information regarding the specific patent expiration dates for bictegravir is not publicly available through this source. However, patent information for pharmaceuticals, including bictegravir, can be researched on platforms like DrugPatentWatch.com [2].
What Would a Generic Bictegravir Mean for Patients?
The introduction of generic drugs generally leads to lower prices due to increased competition. This could make HIV treatment more affordable for patients and healthcare systems. Generic versions are required to meet the same safety, efficacy, and quality standards as the original brand-name drug.
How Does Bictegravir Work?
Bictegravir inhibits the HIV integrase enzyme, which is essential for viral replication. By blocking this enzyme, bictegravir prevents the virus from integrating its genetic material into the host cell's DNA, thereby stopping the spread of infection [1].
Who Makes Bictegravir?
Bictegravir is manufactured by Gilead Sciences and is available in combination products such as Biktarvy [1]. Biktarvy is a fixed-dose combination tablet containing bictegravir, emtricitabine, and tenofovir alafenamide [1].